A new drug, LCZ696, may mark a significant improvement in heart failure treatments. The drug acts as both an angiotensin receptor blocker and utilizes a neprilysin inhibitor, which limits the hormones that cause blood vessel constriction. Scott Solomon, professor of medicine at Brigham and Women’s Hospital, is quoted.
Trending News
Search for Babesiosis Treatment Gets a New Map
New clues to help fight tick-borne disease
Can an AI ‘Co-Scientist’ Accelerate Cancer Research?
Nearly $7 million funds agentic AI tools to assist investigations into cancer’s most pressing…
First Large-Scale Study Shows How Doctors Use AI in Medicine
Which practitioners use artificial intelligence in the clinic, and what do they ask?